Detalles de la búsqueda
1.
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Br J Haematol
; 179(3): 410-420, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28990173
2.
Suboptimal dosing of rituximab in male and female patients with DLBCL.
Blood
; 123(5): 640-6, 2014 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-24297867
3.
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.
Blood
; 124(5): 720-8, 2014 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-24939657
4.
CD4⺠T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemia.
Int J Cancer
; 137(5): 1076-84, 2015 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25677163
5.
Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells.
Blood
; 121(23): 4708-17, 2013 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23580660
6.
Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS/MM.
Int J Cancer
; 135(4): 934-8, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24443359
7.
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Blood
; 119(14): 3276-84, 2012 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22337718
8.
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Cancer Immunol Immunother
; 62(7): 1211-22, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23619976
9.
Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens.
Ann Hematol
; 88(10): 999-1003, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19238384
10.
Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma.
Clin Lymphoma Myeloma
; 8 Suppl 2: S43-9, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18284715
11.
A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing.
Oncogene
; 21(24): 3879-88, 2002 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-12032826
12.
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.
Springerplus
; 3: 5, 2014 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-24455463
13.
Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.
J Clin Oncol
; 32(11): 1112-8, 2014 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24493716
14.
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
J Clin Oncol
; 32(36): 4127-33, 2014 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403207
15.
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.
J Clin Oncol
; 31(32): 4115-22, 2013 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24062391
16.
Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.
Hum Gene Ther
; 23(12): 1224-36, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22966960
17.
Rituximab in high-grade lymphoma.
Semin Hematol
; 47(2): 148-55, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20350662
18.
Unresolved issues in diffuse large B-cell lymphomas.
Expert Rev Anticancer Ther
; 10(3): 387-402, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20214520
19.
Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas.
J Cancer Res Clin Oncol
; 135(9): 1207-13, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19234720
20.
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Ann Hematol
; 87(9): 717-26, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18587579